$DNTH News

Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128

HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158

Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122

Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate

Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027

Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions

Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105

Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate

Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $98

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics CFO Sells $9.5 Million in Stock

How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?

Wells Fargo Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP

Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm